Form 4: Dynavax Director Peter Paradiso Receives Equity Grant Valued at Over $290,000

Dynavax Technologies Corp. Director Peter R. Paradiso was granted 5,758 restricted stock units and 28,500 stock options on June 11, 2025, as part of his compensation.

Summary

• Peter R. Paradiso, a Director of Dynavax Technologies Corp. (DVAX), reported an acquisition of equity securities on June 11, 2025.
• The acquisition included 5,758 Restricted Stock Units (RSUs) at a price of $0 per unit.
• Each RSU represents a contingent right to receive one share of DVAX Common Stock.
• These RSUs will fully vest one year from the grant date (June 11, 2025), provided Mr. Paradiso continues to provide services to the company.
• The release of RSU shares will be mandatorily deferred six months and one day after Mr. Paradiso no longer provides services to the company.
• Additionally, Mr. Paradiso was granted 28,500 stock options with an exercise price of $10.18 per share, also at a price of $0.
• These stock options will fully vest and become exercisable one year from the grant date (June 11, 2025), contingent on continued service.
• The stock options have an expiration date of June 10, 2032.
• Following these transactions, Mr. Paradiso beneficially owns 24,829 shares of Common Stock (RSUs) and 28,500 stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a routine compensation event that aligns the director's interests with shareholders, without any negative implications or surprises.

Positives

• The equity grant aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Granting RSUs and stock options is a common practice for director compensation, reflecting standard corporate governance.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continued service to the company for one year from the grant date, meaning the benefits are not immediate or guaranteed if service ceases.

Future Outlook

The grant of restricted stock units and stock options with a one-year vesting period indicates an expectation of continued service from the director, aligning their future performance with the company's success.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice across industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize key personnel and directors. This grant is consistent with typical compensation structures aimed at aligning leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a common industry standard across publicly traded companies, including those in the biotechnology sector.
• The specific number of units and options granted, as well as the exercise price, would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide specific comparative data.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity securities to Peter R. Paradiso, a Director of Dynavax Technologies Corp., which is a standard form of compensation for a related party.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making aimed at increasing share value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units and Stock Options are expected to vest one year from the grant date, contingent on the director's continued service.

Key Dates

Keywords

Dynavax Technologies, DVAX, Peter R. Paradiso, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership